Antibody Firm Affomix to Collaborate with U of Montreal's PGx Centre on Heart Disease Biomarkers
June 04, 2010
Antibody Firm Affomix to Collaborate with U of Montreal's PGx Centre on Heart Disease Biomarkers
The company will be using its automated, high-throughput monoclonal antibody selection technology to produce several antibodies for each protein target chosen by PGx Centre researchers, enabling them to undertake quantitative, multiplexed profiling of the putative biomarkers.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Fluorotechnics Q2 Revenues Drop to $129K
August 2, 2011 / GenomeWeb Daily News - NGS-Based Peptide Display Platform Enables Proteome-Wide Screening for Autoantigens
May 27, 2011 / ProteoMonitor - Some Proteomics Firms Exploring Next-Generation Sequencing for Biomarker Research
May 6, 2011 / ProteoMonitor - Montreal Heart Institute Developing GnuBio Sequencing Panel for Sudden Cardiac Death Test
February 1, 2012 / Pharmacogenomics Reporter - Knome Raises $5M
August 2, 2011 / GenomeWeb Daily News